cagrilintide semaglutide cagrisema phase 3 results 2024 2025 Novo's disappoint analysts, sending stock tumbling - MM+M Novo Nordisk's CagriSema trial deals
Novo Nordisk's CagriSema trial deals blow in obesity drug battle with Eli Lilly Reuters Cagrilintide lowers bodyweight through brain amylin receptors 1 and 3 eBioMedicine Novo Nordisk's CagriSema 2.4 mg 2.4 mg demonstrated significant reduction in HbA1c and weight across multiple studies in the REIMAGINE program presented at ADA 2026 Cagrilintidesemaglutide (CagriSema) versus semaglutide or cagrilintide in people with type 2 diabetes (REIMAGINE 2): a double blind, randomised, controlled, phase 3 study The Lancet Diabetes & Endocrinology
Pay in 4 interest-free payments of $6.51 Learn more
Shipping Estimate
USA
- USA
- CAN
- USA
- CAN
Ships within 48 hours · Estimated delivery Aug 17 - Aug 22



00125-7/asset/85fa7e17-4785-4f71-9b61-806d7ecb7b4a/main.assets/gr2_lrg.jpg)